Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 ...

Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Click here to find out why PFE stock is ...

A big dividend can’t hide the growth problem at Pfizer (PFE), one of the world’s largest pharmaceutical companies. Pfizer has ...

After GSK’s Lymerix, the only Lyme disease vaccine ever approved, was pulled from the market in 2002 amid a safety ...

A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...

Add Yahoo as a preferred source to see more of our stories on Google. Pfizer is running a Phase III trial of the drug in first-line breast cancer. Credit: ShU studio / Shutterstock.com (ShU studio / ...

High‑yield healthcare stocks are pulling back. See five dividends paying 6% to 14.1% and what their fundamentals reveal for ...

Roche Holding said a drug combination including a new experimental breast-cancer treatment fell short of its primary objective in a late-stage clinical trial. The Swiss pharmaceutical company said ...

Novartis has committed up to $3 billion—two-thirds of that upfront—toward acquiring Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics that specializes in developing PI3Kα inhibitor ...

A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.